Alzheimer’s biology can begin decades before a clinical diagnosis, but most blood-biomarker studies have focused on older adults or people already diagnosed. A Lancet study highlighted by NIH on 1 July shifts the question earlier: what do amyloid-beta and tau in blood correlate with while people are still in midlife? [1][2][3]
The cohort and the signal
Researchers used the long-running CARDIA study and analysed blood samples and cognitive tests from 1,350 participants at a follow-up examination between 2020 and 2022. None had a dementia diagnosis. The team measured three plasma markers, including forms of amyloid-beta and phosphorylated tau that are used as indicators of plaques and tangles in the brain. Depending on the marker and threshold, 4% to 15% of participants had levels high enough to suggest Alzheimer’s-related pathology. [1][2]
Those participants performed worse on processing-speed and executive-function tests. Among people who had taken similar tests five years earlier, higher biomarker levels were also associated with a greater chance of a large decline in processing speed and steeper verbal-memory decline. The association is important, but it is still an association: the cohort does not prove that the blood proteins caused the cognitive changes or that an individual with a high result will develop dementia. [1][2]
Why timing changes the research question
A blood test is easier to repeat than a brain scan or spinal-fluid test, so it could make longitudinal research more practical. It might help investigators recruit prevention trials or study when biological changes begin. That is different from declaring a screening test ready for routine use. The UCSF research group stresses that the paper studied links between plasma markers and midlife cognition, not a clinical diagnosis in symptom-free people. [3]
The useful learning bridge is physical memory architecture. Amyloid plaques, tau tangles, synapses and cognitive tests sit at different levels of the same system. A biomarker is a measurement of one layer; it becomes clinically meaningful only when validated against outcomes, reference standards and a decision that improves care. This distinction is essential because early detection can carry anxiety, cost and false-positive risks as well as potential benefits.
Readers should not use this briefing to interpret a personal result or change medical care. Any real-world test requires a qualified clinician, validated assay and context about symptoms and other conditions. The current evidence supports further research into earlier biology, not a promise about one person’s future.
